Development of Chimeric Antigen Receptor-Expressing iPSC-Derived Macrophages with Improved Anti-Tumor Activity

诱导多能干细胞 生物 吞噬作用 CD80 造血 趋化因子 CD40 免疫学 免疫系统 细胞生物学 癌症研究 干细胞 体外 细胞毒性T细胞 生物化学 基因 胚胎干细胞
作者
Somayeh Pouyanfard,Manuel Fierro,Dan S. Kaufman
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (Supplement 1): 1693-1693 被引量:3
标识
DOI:10.1182/blood-2021-148687
摘要

Abstract Previous studies by our group demonstrate the ability to routinely derive hematopoietic and immune cells from human pluripotent stem cells. Here, we demonstrate the efficient derivation of macrophages from human induced pluripotent stem cells (iPSCs). These macrophages have phenotypic and genotypic characteristics similar to monocytes/macrophages isolated from human peripheral blood. We also demonstrate the ability to polarize these iPSC-derived macrophages (iPSC-Macs) to M1 and M2 populations. Specifically, M1 iPSC-Macs have pro-inflammatory characteristics including expression of CD40 and CD80 on the cell surface, produce increased amounts of TNF-a and IL-6 detected in the supernatant, as well have increased expression of inflammatory cytokines/chemokines (TNF-a, IL-6, IL-1b, IL-12, CCL2, CCL3 and TRAIL) and increased expression of matrix metalloproteases (MMPs). Function of these iPSC-Macs was initially assessed by phagocytosis of fluorescently-labeled beads. These studies demonstrated both the iPSC-M1 and M2 macrophages efficiently phagocytized these beads, and at similar amounts as their peripheral blood counterparts. Next, we tested the ability of the iPSC-Macs to phagocytize human tumor cells. Using A1847 ovarian tumor cells, we found while the iPSC-Macs alone had limited ability to phagocytize the tumor cells (9%), addition of either an anti-CD47 mAb (41%) or anti-EGFR (41%) lead to markedly increased phagocytosis, with the combination of the 2 antibodies being even better (55% phagocytosis). We then tested iPSC-Macs in vivo against luciferase (luc)-expressing A1847 ovarian cancer cells as a xenograft model in NSG-SGM3 mice that express human IL3, GM-CSF and SCF. Using bioluminescent imaging, we found that the combination of iPSC-Macs with both anti-CD47 and anti-EGFR demonstrated significantly improved anti-tumor activity, with median survival of 75 days, compared to 50-60 days for mice treated with only iPSC-Macs, only mAbs or with iPSC-Macs combined either single mAb. Next, we aimed to use the iPSC platform to produce iPSC-Macs engineered to express chimeric antigen receptors (CARs) to further improve their anti-tumor activity. Here, we developed and tested novel macrophage specific CARs that were stably expressed in undifferentiated iPSCs using transposon-mediated gene transfer, similar to our previous studies to derive iPSC-derived CAR-expressing NK cells that have now been translated into clinical trials. We used an anti-mesothelin (meso) scFv combined with 8 different CAR constructs with distinct intracellular signaling components. We found that the iPSC-Macs could express good levels of the CARs (iPSC-CarMacs). Function was again tested in vitro by phagocytosis of the Meso+ A1847 ovarian cancer cells. The iPSC-CarMacs with a Bai1 stimulatory domain consistently demonstrated the best activity in this assay system. We next tested the anti-meso-iPSC-CarMacs in vivo using the A1847 cells. Again, we demonstrate the iPSC-CarMacs combined with anti-CD47 mAb mediate significantly improved anti-tumor activity using this in vivo model compared to the non-CAR-iPSC-Macs + anti-CD47, p <0.005 (Figure). Survival studies are still ongoing. Together, these studies demonstrate that iPSCs can be used to routinely and efficiently derive macrophages with potent anti-tumor activity. Additionally, CARs that are optimized for macrophage-mediated activity can be expressed to generate iPSC-CarMacs that effectively kill tumor cells in vitro and in vivo. These iPSC-CarMacs provide another approach to provide a standardized, targeted, off-the-shelf cell therapy product that can be used to treat both hematological malignancies as well as diverse solid tumors. Figure 1 Figure 1. Disclosures Kaufman: Shoreline Biosciences: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Research Funding; Qihan Biotech: Consultancy, Current holder of stock options in a privately-held company; VisiCELL Medical: Consultancy, Current holder of stock options in a privately-held company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆应助zhang@采纳,获得10
1秒前
感谢cuiyujia转发科研通微信,获得积分50
3秒前
nenoaowu发布了新的文献求助30
3秒前
3秒前
ls1260798887应助水水采纳,获得10
3秒前
不配.应助芦泸采纳,获得10
5秒前
6秒前
7秒前
睡个好觉完成签到,获得积分10
8秒前
交院完成签到,获得积分10
8秒前
cxwong完成签到 ,获得积分10
8秒前
九九关注了科研通微信公众号
9秒前
慕青应助尔玉采纳,获得10
9秒前
无辜又菡发布了新的文献求助10
10秒前
12秒前
优秀娩完成签到,获得积分20
13秒前
14秒前
水水完成签到,获得积分10
15秒前
感谢gd8eij转发科研通微信,获得积分50
15秒前
飞天罗汉果完成签到,获得积分10
15秒前
共享精神应助闪电采纳,获得10
16秒前
优秀娩发布了新的文献求助30
17秒前
痴情的雪萍完成签到,获得积分10
17秒前
慕青应助aurora采纳,获得10
19秒前
19秒前
感谢Huang转发科研通微信,获得积分50
19秒前
所所应助林钟九畹采纳,获得10
19秒前
可爱的函函应助xiaoyi采纳,获得10
20秒前
Kelvin.Tsi完成签到 ,获得积分10
21秒前
22秒前
MU发布了新的文献求助10
24秒前
感谢HuangTingting转发科研通微信,获得积分50
24秒前
悦耳小懒猪完成签到 ,获得积分10
24秒前
26秒前
26秒前
情怀应助CryBill采纳,获得10
27秒前
ssy完成签到 ,获得积分10
27秒前
临江仙完成签到,获得积分10
28秒前
感谢尼仲星转发科研通微信,获得积分50
29秒前
29秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 600
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3234201
求助须知:如何正确求助?哪些是违规求助? 2880628
关于积分的说明 8216151
捐赠科研通 2548179
什么是DOI,文献DOI怎么找? 1377602
科研通“疑难数据库(出版商)”最低求助积分说明 647925
邀请新用户注册赠送积分活动 623302